APELLIS PHARMACEUTICALS INC. - COMMON STOCK

Apellis Announces Submission of New Drug Application to the FDA for Pegcetacoplan for Geographic Atrophy

01 Jun 2022 07:00:01 By Nasdaq GlobeNewswire

Apellis Announces Seven Abstracts in PNH to be Presented at the European Hematology Association Congress

12 May 2022 11:05:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 May 2022 16:23:03 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Present at the Bank of America Securities 2022 Healthcare Conference

05 May 2022 16:05:04 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Reports First Quarter 2022 Financial Results

04 May 2022 16:05:03 By Nasdaq GlobeNewswire

Apellis Announces Dr. Peter Hillmen, Renowned Hematologist and PNH Expert, to Join Company

03 May 2022 07:00:01 By Nasdaq GlobeNewswire

Apellis Announces Detailed 18-Month Results from Phase 3 DERBY and OAKS Studies of Pegcetacoplan for Geographic Atrophy (GA) at ARVO Annual Meeting

02 May 2022 15:30:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Host Conference Call on May 4, 2022 to Discuss First Quarter 2022 Financial Results

26 Apr 2022 07:00:01 By Nasdaq GlobeNewswire

Apellis Announces Results from New Global Survey Conducted by The Harris Poll Revealing the Emotional Burden and Impact on Independence Caused by Geographic Atrophy (GA)

21 Apr 2022 07:00:02 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Present at the 21st Annual Needham Virtual Healthcare Conference

04 Apr 2022 07:00:01 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares

28 Mar 2022 16:01:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock

24 Mar 2022 07:00:01 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Proposed Public Offering of Common Stock

23 Mar 2022 16:02:57 By Nasdaq GlobeNewswire

Apellis Announces Pegcetacoplan Showed Continuous and Clinically Meaningful Effects at Month 18 in Phase 3 DERBY and OAKS Studies for Geographic Atrophy (GA)

16 Mar 2022 07:00:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

02 Mar 2022 07:00:01 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results

28 Feb 2022 16:05:01 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Host Conference Call on February 28, 2022 to Discuss Fourth Quarter and Full Year 2021 Financial Results

22 Feb 2022 07:00:01 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 Jan 2022 16:05:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference

03 Jan 2022 07:00:00 By Nasdaq GlobeNewswire

Apellis and Sobi Announce EU Approval of Aspaveli® (pegcetacoplan) for Treatment of PNH

15 Dec 2021 07:00:00 By Nasdaq GlobeNewswire